Studying Daily Mobithron Advance Tablets for Adults Over 50 With Knee Osteoarthritis to Slow Disease Progression and Assess Safety

What this Trial Is About

Researchers are studying the long-term effects of Mobithron Advance, an oral drug containing undenatured type II collagen, on knee osteoarthritis OA in adults over 50 years old. The trial aims to find out if this drug can slow the progression of OA with Kellgren-Lawrence grade 1 to 3 and to evaluate its safety and long-term impact compared to a placebo. The study is conducted as an early phase 1, single-group trial at the Orthopaedic Clinic of Hospital Universiti Sains Malaysia. Participants will take one Mobithron Advance tablet daily for 12 months. They will undergo assessments including MRI scans at the start, 6 months, and 12 months to measure cartilage thickness in the knee. Pain will be monitored monthly using the Visual Analogue Scale VAS, and physical function will be evaluated with the WOMAC index during follow-up visits at 3, 6, and 12 months. Safety monitoring will include tests of kidney function and recording any adverse events. During the study, participants will have baseline assessments before starting treatment, with follow-up clinic visits every 3 months to assess outcomes and monitor safety. Data collected will cover demographics, clinical results, and imaging findings. Researchers will analyze changes in cartilage thickness, pain levels, physical function, and kidney health over the one-year period to understand how Mobithron Advance affects OA progression and safety.

Long-Term Effects of Mobithron Advance on Knee Osteoarthritis Aims to Investigate the Effects of Mobithron Advance on OA Progression